AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn’s Disease Transcript Finances October 2, 2026 Observe AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Outcomes of Section IIa STENOVA Research in Fibrosing Crohn’s Illness October 1,…
